Merck Stock Climbs on Positive Melanoma Trial Data

Merck & Co., Inc. (ISIN US58933Y1055) is back in the spotlight after releasing new melanoma trial data tied to its cancer program.

The shares were quoted at $148.30 and down 0.80% in the latest market snapshot, with a market capitalization of $368.94 billion as of August 30, 2026.

The positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients was disclosed by Merck and Moderna on August 30, 2026.

This matters because the market is reassessing how a therapy with Phase 3 momentum could widen the long runway for Merck's oncology franchise, which already sits at the center of the company's growth story.